A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma - A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-Small Cell Lung Cancer, o

ELI LILLY & COMPANY, LILLY CORPORATE CENTER0 个研究点目标入组 162 人开始时间: 2020年11月10日最近更新: 2021年1月5日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 162

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: Female

入选标准

•Patients are eligible to be included in the study only if they meet all of the following criteria:
•[1]have brain metastases secondary to histologically or cytologically confirmed HR+ breast cancer, NSCLC, or melanoma.
•[2]Deleted criterion.
•[3]For Parts A,B, D and E: have =1 new or not previously irradiated measurable metastatic brain lesion =10 mm in the longest diameter (LD) or a progressive previously irradiated metastatic brain lesion on radiographic imaging by gadolinium-enhanced magnetic resonance imaging (Gd MRI).
•For Part C (surgical): have metastatic brain lesion(s) for which surgical resection is clinically indicated.
•[4]have completed local therapy (surgical resection, WBRT, or SRS) =14 days prior to initiating abemaciclib and recovered from all acute effects. Patients are not required to have received prior local therapy for study participation.
•[5]if receiving concomitant corticosteroids, must be on a stable or decreasing dose for at least 7 days prior to the baseline Gd-MRI.
•[6]have a Karnofsky performance status of =70 (see Attachment 4)
•[7]have a life expectancy =12 weeks.
•[8]for HR+ breast cancer patients in Parts A, B, C, and F: if currently receiving endocrine therapy, a patient may continue to receive the same endocrine therapy provided that extracranial disease is stable for at least 3 months and CNS disease progression has occurred while on this endocrine therapy. If these conditions are not met, patients must discontinue endocrine therapy prior to initiation of abemaciclib.
•For HER2+ breast cancer patients in Parts A, C, and F: patients may receive concurrent treatment (ongoing or initiated simultaneously with abemaciclib) with intravenous (IV) trastuzumab. Concurrent treatment with trastuzumab emtansine (T-DM1) is not allowed.
•For NSCLC patients in Parts C, D, and F: if currently receiving gemcitabine or pemetrexed (single-agent or in combination with another therapy), a patient may continue to receive 1 of these 2 therapies as a single agent provided that extracranial disease is stable for at least 6 weeks and CNS disease progression has occurred while on this therapy. Combination therapies (aside from gemcitabine or pemetrexed) must be discontinued for at least 14 days prior to initiation of abemaciclib.
•[9]have discontinued all previous therapies for cancer (including cytotoxic chemotherapy, targeted therapy [including, but not limited to, everolimus], radiotherapy, immunotherapy, and investigational therapy) for at least 14 days prior to receiving abemaciclib and recovered from the acute effects of therapy (treatment related toxicity resolved to baseline) except for residual alopecia or peripheral neuropathy.
•[10]for HER2+ breast cancer patients in Parts A, C, and F: patients receiving concurrent IV trastuzumab, must have left ventricular ejection fraction within investigative site’s normal range.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 84
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 36

排除标准

•Patients will be excluded from the study if they meet any of the following criteria:
•[16]require immediate local therapy, including but not limited to WBRT, SRS, or surgical resection, for treatment of brain metastases.
•[17]require concurrent anticancer treatment at any time during the study treatment period.
•[18]are taking concurrent enzyme-inducing antiepileptic drugs (EIAED).
•[19] have evidence of significant (ie, symptomatic) intracranial hemorrhage.
•[20]for Parts A, B, C, D, and E: have evidence of leptomeningeal metastases by clinical signs and symptoms associated with abnormal MRI features or by documented CSF cytology.
•[21]have experienced >2 seizures within 4 weeks prior to study entry.
•[22]have visceral crisis. Visceral crisis is not the mere presence of visceral metastases but implies severe organ dysfunction as assessed by symptoms and signs, laboratory studies, and rapid progression of the disease.
•[23]for Parts A, B, D, E, and F: have previously received treatment with any CDK4 and CDK6 inhibitor. Part C patients may have received prior palbociclib or ribociclib, but not abemaciclib, treatment.
•[24]have known contraindication to Gd-MRI.
•[25]deleted criterion.
•[26]are currently enrolled in a clinical trial involving an investigational product or nonapproved use of a drug or device (other than the study drug used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
•[27]have received treatment with a drug that has not received regulatory approval for any indication within 14 days of the initial dose of abemaciclib.
•[28]have a personal history within the last 12 months of any ventricular arrhythmia (including but not limited to ventricular tachycardia and ventricular fibrillation) or sudden cardiac arrest.
•[29]have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study (for example, history of major surgical resection involving the stomach or small bowel).
•[30]have a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea.
•[31]have a history of any other cancer (except nonmelanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no therapy for a minimum of 3 years.
•[32]are lactating.
•[33]have an active systemic fungal and/or known viral infection (for example, human immunodeficiency virus antibodies, hepatitis B surface antigen, or hepatitis C antibodies). Screening is not required for enrollment.
•[34]have an acute bacterial infection requiring IV antibiotics.
•[35]have received recent (within 28 days of initial dose of abemaciclib) or concurrent yellow fever vaccination.

研究者

发起方

ELI LILLY & COMPANY, LILLY CORPORATE CENTER

相似试验

进行中（未招募）

1 期

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-Small Cell Lung Cancer, or Melanoma That Has Spread to the Brai

EUCTR2014-004010-28-ATEli Lilly and Company247

进行中（未招募）

1 期

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer That Has Spread to the BraiBrain tumours, Breast CancerMedDRA version: 18.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864

EUCTR2014-004010-28-FREli Lilly and Company120

进行中（未招募）

1 期

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-Small Cell Lung Cancer, or Melanoma That Has Spread to the BraiBrain tumours, Breast Cancer, Non-Small Cell Lung Cancer, MelanomaMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000020826

EUCTR2014-004010-28-BEEli Lilly and Company251

进行中（未招募）

1 期

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-Small Cell Lung Cancer, or Melanoma That Has Spread to the BraiBrain tumors, Breast CancerMedDRA version: 18.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864

EUCTR2014-004010-28-ESilly S.A.247

进行中（未招募）

1 期

EUCTR2019-002931-27-BEEli Lilly and Company60